Evidence map›Paper›PMID 42753739›Full record

ArticleImmunity2026

Cancers modulate processing and presentation of p53 neoantigens to evade T cell detection.

Koji Haratani, Bruce Reinhold, Jonathan S Duke-Cohan, Caroline G Fahey, Kemin Tan, Robert J Mallis, Alexander Gusev, Kenneth L Kehl, Jia Luo, Allyson Karmazyn and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Koji HarataniDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Bruce ReinholdDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Laboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jonathan S Duke-CohanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Laboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, MA, USA.
Caroline G FaheyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Kemin TanStructural Biology Center, X-ray Science Division, Advanced Photon Source, Argonne National Laboratory, 9700 S. Cass Avenue, Lemont, IL 60439, USA.
Robert J MallisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Laboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA.
Alexander GusevDivision of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Kenneth L KehlDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Jia LuoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Allyson KarmazynDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA.
Elizabeth L HollidayDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA.
Daniel J MasiDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA.
Katarzyna J ZienkiewiczDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA.
Connor J HennesseyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rafael B BlascoDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.
Tran C ThaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Grace M GibbonsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sophie KivlehanBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick LizotteBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Cloud P PaweletzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew J AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Keith L LigonDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Roberto ChiarleDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10125 Torino, Italy; Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy.
Matthew J LangDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA; Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: david_barbie@dfci.harvard.edu.
Ellis L ReinherzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: ellis_reinherz@dfci.harvard.edu.

Funding

Protein Production CoreP01AI143565 · NIAID · DANA-FARBER CANCER INST · PI Matthew J. Lang, ELLIS L REINHERZ · 2020 to 2026
$19.9M
Project 3P50CA265826 · NCI · DANA-FARBER CANCER INST · PI Daniel Botelho Costa · 2022 to 2026
$13.7M
Targeting the cytokine circuitry of KRAS-driven lung cancerR01CA190394 · NCI · DANA-FARBER CANCER INST · PI David A Barbie · 2015 to 2026
$4.5M
Integrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9M
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapiesR01CA265928 · NCI · DANA-FARBER CANCER INST · PI ELLIS L REINHERZ · 2022 to 2026
$3.4M
An Eiger2 XE 9M detector for the NYSBC-operated NYX beamline at NSLS-IIS10OD030394 · OD · NEW YORK STRUCTURAL BIOLOGY CENTER · PI BATTAILE, KEVIN P · 2021 to 2021
$1.8M
NCI NIH HHS P50 CA265826NCI NIH HHS R01 CA190394NCI NIH HHS R01 CA265928NIAID NIH HHS P01 AI143565NIDDK NIH HHS T32 DK101003NIH HHS S10 OD030394
6 · The paper itself

Abstract

TP53 mutations occur early in malignant transformation as truncal events in tumor evolution and are therefore generally present in all descendant tumor cells, creating an immunological vulnerability. Here, we examined the immunogenicity and antigenicity of p53 neoantigens emerging from these truncal mutations. Comprehensive immunopeptidomics revealed that hotspot mutations in human tumors preferentially localize to p53 regions resistant to antigen processing, thereby avoiding display altogether. Moreover, for neoantigens presentable by HLA-A

Indexed as

antigenicityCTLERAPHLAimmune editingimmunogenicityimmunopeptidomep53T cell receptorTCRTCR performance;truncal neoantigenstumor immunity

Identifiers

PMID42753739
PMCPMC13643599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.